P3 Health Partners INC

P3 Health Partners Inc. subsidiary P3 Health Group, LLC has amended its Repurchase Promissory Note with IHC Health Services, Inc., extending the maturity date to September 30, 2028, and implementing a 14% PIK interest rate.

P3 Health Partners Inc. has successfully regained compliance with Nasdaq's continued listing requirements, as confirmed by a recent notification from Nasdaq.

P3 Health Partners has addressed Nasdaq delisting concerns by converting $252.5 million in debt to preferred equity and raising $30 million in new capital.

P3 Health Partners announced first quarter 2026 financial results, reporting $26 million in adjusted EBITDA and raising full-year adjusted EBITDA guidance to a midpoint of $40 million.

P3 Health Partners has entered into a debt exchange and $70 million capital raise to regain Nasdaq listing compliance.

P3 Health Partners announced Q4 and full-year 2025 results, projecting a significant Adjusted EBITDA improvement and a path to profitability in 2026.

P3 Health Partners Inc. filed its Form 10-Q for the quarter ended March 31, 2026, reporting a net income of $3.04 million, a significant improvement from a net loss of $44.25 million in the prior year period.

P3 Health Partners Inc. reports continued net losses and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern, despite strategic contract terminations and new debt financing.

P3 Health Partners Inc. reported increased net losses and declining revenue for Q2 2025, raising substantial doubt about its ability to continue as a going concern.

P3 Health Partners' Q1 2025 revenue decreased by 4% year-over-year due to a reduction in at-risk members, despite efforts to manage medical expenses and improve operating efficiencies.

P3 Health Partners reported a net loss of $102.9 million for Q3 2024, with substantial doubt about the company's ability to continue as a going concern.

P3 Health Partners saw a 15% increase in revenue year-over-year in the second quarter of 2024, driven by membership growth, but continues to face challenges with profitability and internal controls.

P3 Health Partners Inc. reports continued net losses and substantial doubt about its ability to continue as a going concern, despite efforts to raise capital and strategic adjustments.

P3 Health Partners Inc.'s 2024 10-K filing reveals substantial doubt about the company's ability to continue as a going concern due to significant net losses and debt.

P3 Health Partners Inc.'s 2023 10-K filing reveals a net loss of $186.4 million and concerns about the company's ability to continue as a going concern.

Hudson Vegas Investment SPV, LLC executed a redemption of 50,000 P3 LLC Units for Class A Common Stock.

P3 Health Partners CFO Leif Elliott Pedersen was granted 30,000 stock options with an exercise price of $3.5479.

P3 Health Partners Director Gregory D. Wasson filed an amended Form 4 to correct previously reported stock ownership and disclose a grant of 2,000 restricted stock units.

P3 Health Partners director Mary A. Tolan amends SEC filing to correct beneficial ownership post-reverse stock split and reports new RSU grant.

P3 Health Partners Inc. Director Lawrence B. Leisure filed an amended Form 4 to correct his beneficial ownership following a 1-for-50 reverse stock split.

P3 Health Partners Director Gregory N. Kazarian received a grant of 2,000 restricted stock units, with the filing also correcting his beneficial ownership post-reverse stock split.

P3 Health Partners is holding its annual stockholder meeting on June 4, 2025, to vote on key proposals including the election of directors, ratification of the independent auditor, approval of executive compensation, and the issuance of shares upon warrant exercises.

P3 Health Partners is asking stockholders to approve a reverse stock split to boost its stock price and maintain its Nasdaq listing.

P3 Health Partners announces Aric Coffman as the new CEO, succeeding Sherif Abdou, who transitions to Vice Chairperson and Senior Advisor.

P3 Health Partners Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

P3 Health Partners Inc. will hold its annual stockholder meeting virtually on June 6, 2024, to vote on director elections, auditor ratification, executive compensation, and other matters.

An amendment to a Schedule 13D filing reveals updated beneficial ownership stakes in P3 Health Partners Inc. by Chicago Pacific Founders entities, reflecting a recent financing transaction and a 1-for-50 reverse stock split.

P3 Health Partners Inc. has secured up to $25 million in unsecured financing and issued warrants to an affiliated entity, VBC Growth SPV 3, LLC, to fund ongoing working capital requirements, under terms indicating significant financial strain.